Skip to main content

Day: November 3, 2025

Sysco partners with The MICHELIN Guide for the 2025 Carolinas MICHELIN Guide Ceremony

HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) — Sysco Corporation, the official wholesale food distributor for the prestigious MICHELIN Guide in the Carolinas, is honored to partner to announce the recipients of Michelin’s coveted stars. This partnership will be celebrated at the 2025 MICHELIN Guide Carolinas Ceremony on November 3 in Greenville, S.C., which will showcase Sysco’s high-quality, premium products and culinary expertise. The MICHELIN Guide is renowned for its coveted ratings and in-depth reviews of restaurants worldwide, representing the pinnacle of gastronomic achievement. The November 3 ceremony is the inaugural MICHELIN Guide for the American South and will encompass South Carolina, North Carolina, Alabama, Tennessee, Louisiana and Mississippi, as well as the pre-existing Atlanta Guide. “We are honored to partner with...

Continue reading

Fluke Introduces CalStudio, Software that Drives Efficiency and Collaboration in Calibration Labs

Single software solution eliminates tedious file management tasks, streamlines collaboration, and unlocks greater efficiency and revenue for lab techniciansCalStudio, Software Drives Efficiency and Collaboration in Calibration LabsCalStudio transforms the way labs operate by centralizing knowledge and procedures into a single, cloud-based platform.Everett, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) — Fluke Corporation today announced CalStudio, a software-as-a-service (SaaS)-based solution that transforms the way calibration labs operate by centralizing knowledge and procedures into a single, cloud-based platform. CalStudio empowers technicians to streamline workflows, enhance collaboration across multiple labs, and boost both efficiency and accuracy, driving a new era of productivity and operational excellence in the...

Continue reading

DSG Acquires Quality Pumps, Expanding Onsite Sewer & Water Well Capacity in Madison, Wisconsin Area Market

PLYMOUTH, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) — DSG has announced it has signed a definitive agreement to purchase the assets and business of Quality Pumps in Madison, Wisconsin. The transaction is expected to close in early December. Quality Pumps has served local and regional customers as a trusted wholesale distributor of pumps, pipes, and accessories to well drillers, excavators, and contractors across southern Wisconsin. DSG’s strategic acquisition reinforces its growth-focused commitment to employee owners, customers, manufacturers, and communities. Quality Pumps will continue its operations while transitioning its brand to DSG. All associates will be retained, effectively becoming employee owners of DSG. “DSG’s customer-driven growth is a great fit for our newest employee owners,” said DSG President & CEO Paul Kennedy....

Continue reading

Humanoid Global Unaware of Material Change

Vancouver, BC, Nov. 03, 2025 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF). At the request of CIRO, the Company wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. Humanoid Global is a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, it has a current advertising program that was announced on October 31, 2025. This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of...

Continue reading

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 67th Annual American Society of Hematology (ASH) Annual Meeting taking place from December 6-9, 2025, in Orlando, FL. In addition to the CARVYKTI data, the Company will also deliver an oral presentation on Lucar-G39D, its investigational and novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being evaluated...

Continue reading

Signature Aviation Grows Network with Agreement to Acquire Fort Lauderdale Executive Jet Center

Signature FXE – Fort Lauderdale Executive Jet CenterSignature Aviation, the world’s largest network of private aviation terminals, has signed an agreement to acquire Fort Lauderdale Executive Jet Center, a premier full-service private aviation terminal at Fort Lauderdale Executive Airport (FXE) which offers personalized hospitality, comprehensive aircraft support, and convenient access to the significant business and leisure destinations in the area.    Signature FXE – Fort Lauderdale Executive Jet CenterSignature Aviation, the world’s largest network of private aviation terminals, has signed an agreement to acquire Fort Lauderdale Executive Jet Center, a premier full-service private aviation terminal at Fort Lauderdale Executive Airport (FXE) which offers personalized hospitality, comprehensive aircraft support,...

Continue reading

Information on share capital and voting rights – October 2025

Information on share capital and voting rights October 2025 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. November 3rd, 2025 Statement made by:         Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)DateTotal number of sharesTotal number of voting rightsTheorical (1) Exercisable (2)October 31st, 2025 43,744,779 43,744,779 43,737,270(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles of association...

Continue reading

Zelluna ASA – Contemplates private placement

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, 3 November 2025: Zelluna ASA (“Zelluna” or the “Company”), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer contemplates a private placement of NOK 50-55 million in gross proceeds and a retail offering of new shares through PrimaryBid raising gross...

Continue reading

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 results today. Webcast scheduled for 4 November 2025, at 09:00 (CET). Link to webcast here. Third Quarter 2025 Business Update HighlightsPositive MHRA feedback and strengthened clinical strategy supporting UK clinical developmentIn October 2025 (post period announcement), Zelluna announced it had received positive scientific advice from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The feedback provided alignment across the preclinical, manufacturing, clinical, and regulatory strategy for ZI-MA4-1 and supports the planned Clinical Trial Application (CTA) submission later this year,...

Continue reading

Wolters Kluwer shareholders approve appointment of Ms. Rose Lee and Mr. Hikmet Ersek to the Supervisory Board

PRESS RELEASE Wolters Kluwer shareholders approve appointment ofMs. Rose Lee and Mr. Hikmet Ersek to the Supervisory Board Alphen aan den Rijn, The Netherlands — November 3, 2025 — Wolters Kluwer announces that Ms. Rose Lee and Mr. Hikmet Ersek have been appointed as Members of the Supervisory Board by an Extraordinary General Meeting of Shareholders (“EGM”) held today. The appointments are effective immediately and are for the period starting November 3, 2025, and ending after the AGM to be held in 2030. Both candidates are seasoned executives with extensive managerial and Board experience in complex industries. Their appointment will further strengthen the Supervisory Board’s ability to oversee and support the company’s strategic direction aimed at long-term value creation. Ms. Lee is former CEO and Board member of Cornerstone Building...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.